Vaxcyte’s (PCVX) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Vaxcyte (NASDAQ:PCVX) in a research report sent to investors on Tuesday,Weiss Ratings reports.

A number of other research firms have also recently issued reports on PCVX. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price for the company. Cowen reissued a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.25.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $43.59 on Tuesday. The firm’s 50-day simple moving average is $34.35 and its 200-day simple moving average is $33.65. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $118.54. The firm has a market cap of $5.66 billion, a P/E ratio of -10.61 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter last year, the business posted ($1.10) EPS. On average, equities analysts forecast that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

A number of large investors have recently modified their holdings of PCVX. GAMMA Investing LLC lifted its position in shares of Vaxcyte by 2,631.8% during the first quarter. GAMMA Investing LLC now owns 9,780 shares of the company’s stock worth $369,000 after purchasing an additional 9,422 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Vaxcyte by 61.3% during the first quarter. SG Americas Securities LLC now owns 14,520 shares of the company’s stock worth $548,000 after purchasing an additional 5,520 shares in the last quarter. Avior Wealth Management LLC lifted its position in shares of Vaxcyte by 5.3% during the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company’s stock worth $257,000 after purchasing an additional 343 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in shares of Vaxcyte during the first quarter worth approximately $3,257,000. Finally, J.Safra Asset Management Corp lifted its position in shares of Vaxcyte by 65.8% during the first quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company’s stock worth $119,000 after purchasing an additional 1,254 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.